|
1
|
Landis SH, Murray T, Bolden S and Wingo
PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999.
View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
3
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel
E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM,
Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR:
Rethinking ovarian cancer: recommendations for improving outcomes.
Nat Rev Cancer. 11:719–725. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
5
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnson SW, Ozols RF and Hamilton TC:
Mechanisms of drug resistance in ovarian cancer. Cancer. 71(Suppl
2): S644–S649. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Osborne C, Wilson P and Tripathy D:
Oncogenes and tumor suppressor genes in breast cancer: potential
diagnostic and therapeutic applications. Oncologist. 9:361–377.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van Waardenburg RC, Prins J, Meijer C,
Uges DR, De Vries EG and Mulder NH: Effects of c-myc oncogene
modulation on drug resistance in human small cell lung carcinoma
cell lines. Anticancer Res. 16:1963–1970. 1996.
|
|
11
|
Kumari R, Li H, Haudenschild DR, Fierro F,
Carlson CS, Overn P, Gupta L, Gupta K, Nolta J, Yik JH and Di
Cesare PE: The oncogene LRF is a survival factor in chondrosarcoma
and contributes to tumor malignancy and drug resistance.
Carcinogenesis. 33:2076–2083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barre B, Vigneron A, Perkins N, Roninson
IB, Gamelin E and Coqueret O: The STAT3 oncogene as a
predictive marker of drug resistance. Trends Mol Med. 13:4–11.
2007.
|
|
13
|
Zhao M, Sun J and Zhao Z: Distinct and
competitive regulatory patterns of tumor suppressor genes and
oncogenes in ovarian cancer. PLoS One. 7:e441752012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ratner ES, Keane FK, Lindner R, Tassi RA,
Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S,
Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S,
Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford
TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD and
Weidhaas JB: A KRAS variant is a biomarker of poor outcome,
platinum chemotherapy resistance and a potential target for therapy
in ovarian cancer. Oncogene. 31:4559–4566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu L, Wu A and Jiang K: Effect of
antisense c-erbB2 on biologic behaviour and chemotherapeutic drug
sensitivity in human ovarian cancer cells. Zhonghua Fu Chan Ke Za
Zhi. 31:169–172. 1996.(In Chinese).
|
|
16
|
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes
KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ,
Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale
K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr
and Mills GB: Perifosine plus docetaxel in patients with platinum
and taxane resistant or refractory high-grade epithelial ovarian
cancer. Gynecol Oncol. 126:47–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stronach EA, Alfraidi A, Rama N, Datler C,
Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB,
Mai A, Brown R, Dina R and Gabra H: HDAC4-regulated STAT1
activation mediates platinum resistance in ovarian cancer. Cancer
Res. 71:4412–4422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fry AM, Schultz SJ, Bartek J and Nigg EA:
Substrate specificity and cell cycle regulation of the Nek2 protein
kinase, a potential human homolog of the mitotic regulator NIMA of
Aspergillus nidulans. J Biol Chem. 270:12899–12905. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee J and Gollahon L: Nek2-targeted ASO or
siRNA pretreatment enhances anticancer drug sensitivity in
triplenegative breast cancer cells. Int J Oncol. 42:839–847.
2013.PubMed/NCBI
|
|
21
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R,
Bearss D, Tricot G and Zhan F: NEK2 induces drug resistance
mainly through activation of efflux drug pumps and is associated
with poor prognosis in myeloma and other cancers. Cancer Cell.
23:48–62. 2013. View Article : Google Scholar
|
|
22
|
Harrison C: Cancer: a target for drug
resistance. Nat Rev Drug Discov. 12:1902013. View Article : Google Scholar
|
|
23
|
Barrett T and Edgar R: Mining microarray
data at NCBI’s Gene Expression Omnibus (GEO)*. Methods
Mol Biol. 338:175–190. 2006.
|
|
24
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: a real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9(Suppl 1): S42008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Leeuw N, Dijkhuizen T, Hehir-Kwa JY,
Carter NP, Feuk L, Firth HV, Kuhn RM, Ledbetter DH, Martin CL, van
Ravenswaaij-Arts CM, Scherer SW, Shams S, Van Vooren S, Sijmons R,
Swertz M and Hastings R: Diagnostic interpretation of array data
using public databases and internet sources. Hum Mutat. Feb
14–2012.(Epub ahead of print). View Article : Google Scholar
|
|
26
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011.
|
|
27
|
Fry AM, O’Regan L, Sabir SR and Bayliss R:
Cell cycle regulation by the NEK family of protein kinases. J Cell
Sci. 125:4423–4433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andersen JS, Wilkinson CJ, Mayor T,
Mortensen P, Nigg EA and Mann M: Proteomic characterization of the
human centrosome by protein correlation profiling. Nature.
426:570–574. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fry AM, Meraldi P and Nigg EA: A
centrosomal function for the human Nek2 protein kinase, a member of
the NIMA family of cell cycle regulators. EMBO J. 17:470–481. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayward DG, Clarke RB, Faragher AJ, Pillai
MR, Hagan IM and Fry AM: The centrosomal kinase Nek2 displays
elevated levels of protein expression in human breast cancer.
Cancer Res. 64:7370–7376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cappello P, Blaser H, Gorrini C, Lin DC,
Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA,
Youngson B, Done SJ and Mak TW: Role of Nek2 on centrosome
duplication and aneuploidy in breast cancer cells. Oncogene. May
27–2013.(Epub ahead of print). View Article : Google Scholar
|
|
32
|
Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang
J, Liu T and Niu Y: Abnormal expression of Nek2 and β-catenin in
breast carcinoma: clinicopathological correlations. Histopathology.
59:631–642. 2011.
|
|
33
|
Wang H, Xie YT, Han JY, Ruan Y, Song AP,
Zheng LY, Zhang WZ, Sajdik C, Li Y, Tian XX and Fang WG: Genetic
polymorphisms in centrobin and Nek2 are associated
with breast cancer susceptibility in a Chinese Han population.
Breast Cancer Res Treat. 136:241–251. 2012.
|
|
34
|
Liu Z, Wang Y, Wang S, Zhang J, Zhang F
and Niu Y: Nek2C functions as a tumor promoter in human breast
tumorigenesis. Int J Mol Med. 30:775–782. 2012.PubMed/NCBI
|
|
35
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW,
Murphy SE, Yang P, Pesatori AC, Consonni D, Bertazzi PA, Wacholder
S, Shih JH, Caporaso NE and Jen J: Gene expression signature of
cigarette smoking and its role in lung adenocarcinoma development
and survival. PLoS One. 3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koch M and Wiese M: Gene expression
signatures of angiocidin and darapladib treatment connect to
therapy options in cervical cancer. J Cancer Res Clin Oncol.
139:259–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hawkins SM, Loomans HA, Wan YW,
Ghosh-Choudhury T, Coffey D, Xiao W, Liu Z, Sangi-Haghpeykar H and
Anderson ML: Expression and functional pathway analysis of nuclear
receptor NR2F2 in ovarian cancer. J Clin Endocrinol Metab.
98:E1152–E1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Suzuki K, Kokuryo T, Senga T, Yokoyama Y,
Nagino M and Hamaguchi M: Novel combination treatment for
colorectal cancer using Nek2 siRNA and cisplatin. Cancer Sci.
101:1163–1169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gudmundsdottir K and Ashworth A: The roles
of BRCA1 and BRCA2 and associated proteins in the maintenance of
genomic stability. Oncogene. 25:5864–5874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang F, Fan Q, Ren K and Andreassen PR:
PALB2 functionally connects the breast cancer susceptibility
proteins BRCA1 and BRCA2. Mol Cancer Res. 7:1110–1118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao D, Zhang W, Li XG, Wang XB, Li M, Li
YF, Tian HM, Song PP, Liu J, Chang QY and Wu LY: The mRNA
expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their
relationship with clinical chemosensitivity in primary epithelial
ovarian cancer. Zhonghua Zhong Liu Za Zhi. 34:196–200. 2012.(In
Chinese).
|
|
42
|
Lu L, Katsaros D, Wiley A, Rigault de la
Longrais IA, Puopolo M and Yu H: Expression of MDR1 in epithelial
ovarian cancer and its association with disease progression. Oncol
Res. 16:395–403. 2007.PubMed/NCBI
|
|
43
|
Sakai W, Swisher EM, Jacquemont C,
Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas
E and Taniguchi T: Functional restoration of BRCA2 protein
by secondary BRCA2 mutations in BRCA2-mutated ovarian
carcinoma. Cancer Res. 69:6381–6386. 2009.
|
|
44
|
Scully R, Chen J, Plug A, Xiao Y, Weaver
D, Feunteun J, Ashley T and Livingston DM: Association of BRCA1
with Rad51 in mitotic and meiotic cells. Cell. 88:265–275. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou
J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene
PTEN on the resistance to cisplatin in human ovarian cancer cell
lines and related mechanisms. Cancer Lett. 271:260–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yan X, Fraser M, Qiu Q and Tsang BK:
Over-expression of PTEN sensitizes human ovarian cancer cells to
cisplatin-induced apoptosis in a p53-dependent manner. Gynecol
Oncol. 102:348–355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang P, Gao W, Li H, Reed E and Chen F:
Inducible degradation of checkpoint kinase 2 links to
cisplatin-induced resistance in ovarian cancer cells. Biochem
Biophys Res Commun. 328:567–572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang X, Yashiro M, Qiu H, Nishii T,
Matsuzaki T and Hirakawa K: Establishment and characterization of
multidrug-resistant gastric cancer cell lines. Anticancer Res.
30:915–921. 2010.PubMed/NCBI
|
|
49
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Tumor suppressor genes associated with drug resistance in
ovarian cancer (Review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
|
|
50
|
He G, Kuang J, Khokhar AR and Siddik ZH:
The impact of S- and G2-checkpoint response on the fidelity of
G1-arrest by cisplatin and its comparison to a non-cross-resistant
platinum(IV) analog. Gynecol Oncol. 122:402–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Plumb JA, Strathdee G, Sludden J, Kaye SB
and Brown R: Reversal of drug resistance in human tumor xenografts
by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1
gene promoter. Cancer Res. 60:6039–6044. 2000.
|
|
52
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in
loss of hMLH1 expression and drug resistance in ovarian cancer.
Oncogene. 18:2335–2341. 1999.PubMed/NCBI
|
|
53
|
Zhang X, Wang X, Song X, Liu C, Shi Y,
Wang Y, Afonja O, Ma C, Chen YH and Zhang L: Programmed cell death
4 enhances chemosensitivity of ovarian cancer cells by activating
death receptor pathway in vitro and in vivo. Cancer Sci.
101:2163–2170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Reles A, Wen WH, Schmider A, Gee C,
Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C,
Schönborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF:
Correlation of p53 mutations with resistance to
platinum-based chemotherapy and shortened survival in ovarian
cancer. Clin Cancer Res. 7:2984–2997. 2001.
|
|
55
|
Al-Bahlani S, Fraser M, Wong AY, Sayan BS,
Bergeron R, Melino G and Tsang BK: P73 regulates cisplatin-induced
apoptosis in ovarian cancer cells via a calcium/calpain-dependent
mechanism. Oncogene. 30:4219–4230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu YY, Li L, Li DR, Zhang W and Wang Q:
Suppression of WWOX gene by RNA interference reverses platinum
resistance acquired in SKOV3/SB cells. Zhonghua Fu Chan Ke Za Zhi.
43:854–858. 2008.(In Chinese).
|
|
57
|
Takai N and Narahara H: Histone
deacetylase inhibitor therapy in epithelial ovarian cancer. J
Oncol. 2010:4584312010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Auner V, Sehouli J, Oskay-Oezcelik G,
Horvat R, Speiser P and Zeillinger R: ABC transporter gene
expression in benign and malignant ovarian tissue. Gynecol Oncol.
117:198–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fink D, Nebel S, Aebi S, Nehme A and
Howell S: Loss of DNA mismatch repair due to knockout of MSH2 or
PMS2 results in resistance to cisplatin and carboplatin. Int J
Oncol. 11:539–542. 1997.PubMed/NCBI
|
|
60
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: an emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
61
|
Li M, Balch C, Montgomery JS, Jeong M,
Chung JH, Yan P, Huang TH, Kim S and Nephew KP: Integrated analysis
of DNA methylation and gene expression reveals specific signaling
pathways associated with platinum resistance in ovarian cancer. BMC
Med Genomics. 2:342009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Gregory-Bass RC, Olatinwo M, Xu W,
Matthews R, Stiles JK, Thomas K, Liu D, Tsang B and Thompson WE:
Prohibitin silencing reverses stabilization of mitochondrial
integrity and chemoresistance in ovarian cancer cells by increasing
their sensitivity to apoptosis. Int J Cancer. 122:1923–1930. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Koshkin V and Krylov SN: Correlation
between multi-drug resistance-associated membrane transport in
clonal cancer cells and the cell cycle phase. PLoS One.
7:e413682012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fojo T and Menefee M: Mechanisms of
multidrug resistance: the potential role of microtubule-stabilizing
agents. Ann Oncol. 18(Suppl 5): v3–v8. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kassler S, Donninger H, Birrer MJ and
Clark GJ: RASSF1A and the taxol response in ovarian cancer. Mol
Biol Int. 2012:2632672012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pellicciotta I, Yang CP, Venditti CA,
Goldberg GL and Shahabi S: Response to microtubule-interacting
agents in primary epithelial ovarian cancer cells. Cancer Cell Int.
13:332013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L
and Wang Z: MiR-27a modulates MDR1/P-glycoprotein expression by
targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol.
119:125–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Husted S, Søkilde R, Rask L, Cirera S,
Busk PK, Eriksen J and Litman T: MicroRNA expression profiles
associated with development of drug resistance in Ehrlich ascites
tumor cells. Mol Pharm. 8:2055–2062. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Vang S, Wu HT, Fischer A, Miller DH,
MacLaughlan S, Douglass E, Steinhoff M, Collins C, Smith PJ, Brard
L and Brodsky AS: Identification of ovarian cancer metastatic
miRNAs. PLoS One. 8:e582262013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang Y, Chuang A, Hao H, Talbot C, Sen T,
Trink B, Sidransky D and Ratovitski E: Phospho-ΔNp63α is a key
regulator of the cisplatin-induced microRNAome in cancer cells.
Cell Death Differ. 18:1220–1230. 2011.
|
|
71
|
Galluzzi L, Morselli E, Vitale I, Kepp O,
Senovilla L, Criollo A, Servant N, Paccard C, Hupé P, Robert T,
Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E and
Kroemer G: miR-181a and miR-630 regulate cisplatin-induced cancer
cell death. Cancer Res. 70:1793–1803. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Srivastava N, Manvati S, Srivastava A, Pal
R, Kalaiarasan P, Chattopadhyay S, Gochhait S, Dua R and Bamezai
RN: miR-24–2 controls H2AFX expression regardless of gene
copy number alteration and induces apoptosis by targeting
antiapoptotic gene BCL-2: a potential for therapeutic
intervention. Breast Cancer Res. 13:R392011.
|
|
73
|
Ji S, Shao G, Lv X, Liu Y, Fan Y, Wu A and
Hu H: Downregulation of miRNA-128 sensitises breast cancer cell to
chemodrugs by targeting Bax. Cell Biol Int. 37:653–658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Deng M, Tang H, Zhou Y, Zhou M, Xiong W,
Zheng Y, Ye Q, Zeng X, Liao Q, Guo X, Li X, Ma J and Li G: miR-216b
suppresses tumor growth and invasion by targeting KRAS in
nasopharyngeal carcinoma. J Cell Sci. 124:2997–3005. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kim SY, Lee YH and Bae YS: MiR-186,
miR-216b, miR-337-3p, and miR-760 cooperatively induce cellular
senescence by targeting α subunit of protein kinase CKII in human
colorectal cancer cells. Biochem Biophys Res Commun. 429:173–179.
2012.PubMed/NCBI
|
|
76
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue
JM, Stass SA, Xing L and Jiang F: Downregulation of miR-486-5p
contributes to tumor progression and metastasis by targeting
protumorigenic ARHGAP5 in lung cancer. Oncogene. Mar 11–2013.(Epub
ahead of print). View Article : Google Scholar
|
|
77
|
Yin F, Liu X, Li D, Wang Q, Zhang W and Li
L: Bioinformatic analysis of chemokine (C-C motif) ligand 21 and
SPARC-like protein 1 revealing their associations with drug
resistance in ovarian cancer. Int J Oncol. 42:1305–1316.
2013.PubMed/NCBI
|
|
78
|
Jiang X, Gold D and Kolaczyk ED:
Network-based auto-probit modeling for protein function prediction.
Biometrics. 67:958–966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sharan R, Ulitsky I and Shamir R:
Network-based prediction of protein function. Mol Syst Biol.
3:882007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Barrett T and Edgar R: Gene expression
Omnibus: microarray data storage, submission, retrieval, and
analysis. Methods Enzymol. 411:352–369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD and
Morris Q: The GeneMANIA prediction server: biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jenssen TK, Laegreid A, Komorowski J and
Hovig E: A literature network of human genes for high-throughput
analysis of gene expression. Nat Genet. 28:21–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yi B, Piazza GA, Su X and Xi Y: MicroRNA
and cancer chemoprevention. Cancer Prev Res. 6:401–409. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tili E, Michaille JJ, Gandhi V, Plunkett
W, Sampath D and Calin GA: miRNAs and their potential for use
against cancer and other diseases. Future Oncol. 3:521–537. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tanaka K, Parvinen M and Nigg EA: The in
vivo expression pattern of mouse Nek2, a NIMA-related kinase,
indicates a role in both mitosis and meiosis. Exp Cell Res.
237:264–274. 1997. View Article : Google Scholar : PubMed/NCBI
|
